Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048279 · ClinicalTrials.gov registry record
Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
A clinical trial of Multiple Endocrine Neoplasia Syndromes, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT03048279: Active study of Multiple Endocrine Neoplasia Syndromes, sponsored by M.D. Anderson Cancer Center.
NCT03048279 is a study of Multiple Endocrine Neoplasia Syndromes that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03048279, a study of Multiple Endocrine Neoplasia Syndromes, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: To contribute new and prospective data to our existing database library for patients with MEN1 and MEN2 at The University of Texas M.D. Anderson Cancer Center.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2001-09-05 |
| Est. Completion | 2026-09-01 |
What the registry record for NCT03048279 still lists
NCT03048279 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Multiple Endocrine Neoplasia Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT03048279 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03048279 about?
NCT03048279 is a clinical study titled "Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2". Objectives: To contribute new and prospective data to our existing database library for patients with MEN1 and MEN2 at The University of Texas M.D. Anderson Cancer Center.
What is the current status of trial NCT03048279?
This trial is currently active not recruiting. The enrollment target is 1,500 participants. The study started on 2001-09-05. Estimated completion is 2026-09-01.
What conditions does trial NCT03048279 study?
This clinical trial studies the following conditions: Multiple Endocrine Neoplasia Syndromes.
What interventions are being tested in trial NCT03048279?
The interventions under investigation include: Questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT03048279?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03048279 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI